There's a growing recognition that the molecular profile of a primary tumor can differ significantly from its metastases. To guide treatment more accurately, the preferred practice is to biopsy an accessible metastatic lesion when possible, as this better reflects the biology of the active disease being treated.

Every cancer specimen is genetically unique, yet all share common traits like uncontrolled division and co-opting normal cell survival mechanisms. The key to treatment is finding pathways that are different enough from normal cells to target and exploit.

While revolutionary for liquid tumors, CAR-T cells struggle to attack solid tumors. The tumor's 'microenvironment'—a complex ecosystem of blood vessels, immune cells, and supportive structures—acts as a physical and biological barrier that prevents the engineered T-cells from reaching their target.

The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

Unlike immune cells engineered to kill tumors (e.g., CAR-T), Mesenchymal Stem Cells (MSCs) solve a different problem. Their primary role is to leverage natural trafficking ability to reach the tumor microenvironment and deliver therapeutic payloads, rather than acting as immune effectors themselves.

Injecting a genetic medicine into one tumor can trigger an 'abscopal response,' where the immune system learns to recognize the cancer. This educated immune system then travels throughout the body to find and destroy other metastatic tumors, even those in deep organs like the lungs, which are typically the fatal ones.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

The characteristic that makes stem cells invaluable—their ability to self-renew for a lifetime—is the same immortalization program that cancer cells hijack to grow without constraint. This highlights cancer's parasitic relationship with a fundamental biological process needed for survival.

A tumor can be viewed as an evolving system within the body's environment. It progresses from stage to stage by "ratcheting up" its functional information—its ability to survive and grow. This evolutionary framework could inspire novel cancer treatments.